21 May 2013
Keywords: wilex, wx-671, enters, clinic, ag, germany, initiated
Article | 27 September 2004
Wilex AG of Germany has initiated a Phase I trial of its new oral, non-cytotoxic anticancer compound WX-671. The open-label,
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 September 2004
20 May 2013
© 2013 thepharmaletter.com